Role of HDL-Associated Proteins and Lipids in the Regulation of Inflammation by White, Roger et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Role of HDL-Associated Proteins and Lipids in the
Regulation of Inflammation
Roger White, Samantha Giordano and Geeta Datta
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67141
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
egulation of Inflammation
Roger White, Samantha Giordano and 
Geeta Datta
Additional information is available at the end of the chapter
Abstract
Lipoproteins are complexes of lipids and proteins that carry water‐insoluble cholesterol 
in the bloodstream. While cholesterol is required for normal cell function, hypercholes‐
terolemia contributes to the development of cardiovascular disease (CVD). Increased 
low‐density lipoprotein (LDL) is a major risk factor for CVD. Reduced high‐density lipo‐
protein (HDL) levels are inversely related to CVD risk, suggesting a protective role for 
HDL. Several diseases, including atherosclerosis, diabetes, chronic kidney disease and 
rheumatoid arthritis, have been identified where HDL levels are decreased or function is 
compromised. HDLs are spherical particles with a hydrophobic core of cholesteryl esters 
surrounded by a monolayer of phospholipids, proteins and unesterified cholesterol. 
Apolipoprotein (apo) A‐I, the major protein component of HDL, plays an important role 
in the assembly and function of HDL. One of the major functions of HDL is to mediate 
cellular cholesterol efflux and the transfer of cholesterol from extrahepatic tissues to the 
liver for excretion into the bile. In addition to regulating cholesterol metabolism, HDL 
also exhibits antioxidative, antithrombotic and anti‐inflammatory properties. Under cer‐
tain conditions, however, HDL may undergo biochemical modification resulting in the 
formation of a particle with pro‐inflammatory properties. This review will focus on the 
variable properties of HDL under normal physiological conditions and in the context of 
inflammation.
Keywords: HDL, inflammation, lipid composition, protein composition, function, 
macrophage mitochondria
1. Introduction
Hypercholesterolemia is an important determinant of cardiovascular disease (CVD), the lead‐
ing cause of death globally [1]. Cholesterol, among other lipids, is carried in the bloodstream 
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from the liver to different parts of the body by lipoproteins, complex particles composed of 
lipids and proteins. There are four major lipoproteins that can be classified on the basis of 
their density: chylomicrons, very low‐density lipoprotein (VLDL), low‐density lipoprotein 
(LDL) and high‐density lipoprotein (HDL) [2]. Chylomicrons, VLDL and LDL are larger par‐
ticles with densities ranging from 0.95 to 1.063 g/ml. HDL is a mixture of spherical particles 
ranging in size from 7 to 12 nm in diameter and 1.063–1.21 g/ml in density. Epidemiological 
studies have established an inverse relationship between HDL cholesterol and CVD risk [3, 4]. 
Thus, a reduction in plasma HDL levels represents an important risk factor for CVD. Results 
of clinical trials demonstrate that lowering LDL levels reduces CVD risk [5, 6]. Evidence sup‐
porting a role for elevated HDL in reducing CVD risk, however, is still forthcoming. Clinical 
trials have shown that torcetrapib, dalcetrapib and extended‐release niacin significantly 
increase circulating HDL levels; however, this was not associated with improved outcomes 
[7–9]. On the other hand, raising plasma HDL by infusion or overexpression of apoA‐I in 
murine models was shown to reduce atherogenic lesion progression [10]. One hypothesis to 
explain this disparity proposes that the “quality” or functional status of HDL may be a better 
indicator of CVD risk than plasma levels of HDL per se [11]. This review will focus on the 
structure‐function relationship of HDL and how it influences responses to the lipoprotein in 
the context of inflammation.
HDL particles have a neutral core of cholesteryl ester and triglycerides (TG) surrounded 
by a monolayer of phospholipids, free cholesterol (FC) and protein. ApoA‐I is the major 
protein associated with HDL particles and is synthesized in the liver and small intestine. 
Phospholipids and cholesterol are transferred to apoA‐I by a process mediated by the ATP‐
binding cassette transporter type 1 (ABCA1) [12, 13] resulting in the formation of a lipid poor, 
dense particle called preβ‐HDL. This particle plays an important role in reverse cholesterol 
transport, a process by which cholesterol is removed from cells. Although these particles 
have been predominantly studied under in vitro conditions, little information is available 
regarding the presence or functional significance of preβ‐HDL in vivo [14]. HDL isolated 
from plasma by sequential ultracentrifugation yields two major subpopulations: HDL2, a 
large, light, lipid‐rich particle (d1.063–1.125 g/ml), and HDL3, a smaller, denser protein‐rich 
particle (d1.125–1.21 g/ml). These two particles can be further subdivided into five distinct 
populations: HDL2b, HDL2a, HDL3a, HDL3b and HDL3c [15]. These heterogeneous particles 
vary in their lipid and protein composition, forming particles of varying density, charge, and 
antigenicity. They also possess discrete functional properties.
2. HDL structural components
The HDL lipidome: Phospholipids (PL) represent the major lipid component of HDL, con‐
stituting about 50% by weight of all the lipids [15]. Phosphatidylcholine (PC), with a carbon 
backbone of varying length and saturation, is the major PL species. Lysophosphatidylcholine 
(LPC), phosphatidylethanolamine (PE), phosphatidylinositol (PI) and plasmalogens are also 
present at lower, but significant, amounts (greater than 1% of total HDL lipids by weight). 
Other phospholipids (phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidic acid 
(PA) and cardiolipin) constitute less than 1% of total HDL lipids by weight.
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Sphingolipids are also well‐represented in HDL particles. Sphingomyelin (SM) accounts for 
5–10% by weight of total HDL lipids [15]. SM is converted to ceramide by sphingomyelin‐
ase [16]. Ceramide constitutes 0.05% by weight of total HDL lipids. Ceraminidase converts 
ceramide to sphingosine. Finally, the enzyme sphingosine kinase converts sphingosine to 
sphingosine 1‐phosphate (S1P) [16]. S1P, as well as ceramide‐1‐phosphate, are carried by 
HDL and are potent signaling molecules that regulate cell growth, survival and differentia‐
tion [17]. S1P plays an important role in the suppression of inflammation [17]. S1P binding to 
HDL requires its physical interaction with apo M [17, 18]. Sphingosylphosphorylcholine and 
lysosulfatide are additional, biologically active lysosphingolipids carried by HDL [15]. The 
principal lipids associated with HDL particles are summarized in Table 1.
The HDL proteome: The HDL proteome has been characterized by several groups over the 
past 10 years. Using mass spectroscopy, the presence of at least 85 proteins on HDL have been 
reported [19]. These fall into different regulatory categories: lipid metabolism, acute phase 
response (APR), hemostasis, immune response, metal binding, vitamin transport, proteinase 
inhibitor and complement regulation [19, 20]. A representative list of HDL‐associated pro‐
teins is shown in Table 1. Among these, the lipid metabolism group is the largest and con‐
tains apoA‐I as well as other apolipoproteins (Table 1). As mentioned above, HDL exists as 
multiple sub‐species. The proteins, lecithin‐cholesterol acyltransferase (LCAT), phospholipid 
transfer protein (PLTP) and cholesteryl ester transfer protein (CETP), play a major role in 
converting HDL from one sub‐species to another. APR proteins such as apo A‐IV, SAA1 and 
SAA2 regulate lipid metabolism and are also present along with Apo J, a protein involved in 
Proteins Lipids
Apolipoproteins (AI‐II, A‐V, C‐I‐IV, D, E, F, M, H, O) Phospholipids:
CETP PC, PE, PI, PG, PS, PA
PAF‐AH
PLTP Sphingolipids:
LCAT SM
PON1, PON3 Ceramides
SAA1, SAA2, SAA4 S1P
Albumin Sphingosylphosphorylcholine
Transthyretin Lysosulfatide
Hemoglobin
Hemopexin
Transferrin
Ceruloplasmin
Vitamin D binding protein
Complement
Table 1. Normal protein and lipid components of HDL.
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lipid metabolism and complement regulation. Surprisingly, a variety of other proteins with 
diverse functions such as hemoglobin, hemopexin and transferrin (iron metabolism), ceru‐
loplasmin (metal binding), and vitamin D binding protein (vitamin binding) are also seen. 
These are described in detail in the review by Shah et al. [19]. Thus, the protein and lipid cargo 
on HDL significantly influence particle function.
3. Functions of HDL
Reverse cholesterol transport: Under hypercholesterolemic conditions, the accumulation of 
cholesterol in macrophages leads to the formation of “foam cells” which contribute to ath‐
eroma formation. HDL is commonly referred to as the “good cholesterol”. The salutary effect 
of HDL has been attributed to its ability to transfer cholesterol from extra‐hepatic tissues to 
the liver for metabolism and excretion into the bile, a process called reverse cholesterol trans‐
port [21]. This is believed to be a critical antiatherogenic function of HDL. Cholesterol from 
macrophages is transferred to lipid‐poor apoA‐I [22] via ABCA1. The cholesterol is converted 
to cholesterol esters by the action of LCAT present on HDL. Sequestration of cholesterol esters 
in the hydrophobic core of the particle is associated with the formation of spherical HDL2 and 
HDL3. These mature HDL particles also incorporate cholesterol via an alternate transporter, 
the ATP‐binding cassette transporter G1 (ABCG1) as well as the scavenger‐receptor class B, 
type 1 (SR‐BI) pathway [23]. Cholesterol‐enriched HDL is subsequently removed from the 
circulation by hepatocytes and is excreted by the biliary pathway into bile and feces. In addi‐
tion to mediating reverse cholesterol transport, HDL also possesses antioxidant, anti‐inflam‐
matory and antithrombotic properties. These pleiotropic effects of HDL play a major role in 
limiting inflammatory injury associated with leukocyte infiltration in the blood vessel wall.
Antioxidant properties of HDL: Chylomicrons, VLDL and LDL are apoB‐containing lipo‐
proteins which deliver cholesterol and TG to cells and are strongly implicated in atheroma 
formation. The response‐to‐retention hypothesis postulates that [24] LDL is oxidized in the 
arterial wall by enzymes including myeloperoxidase (MPO), NADPH oxidase, nitric oxide 
synthase and lipoxygenase, resulting in the accumulation of lipid hydroperoxides (LOOH) 
[25]. Oxidized LDL (ox‐LDL) is taken up by macrophages leading to the formation of foam 
cells and fatty plaques. Protein and lipid components of HDL inhibit the accumulation of 
LOOH in LDL and prevent the formation of ox‐LDL. LOOH and phosphatidyl choline hydro‐
peroxides (PLOOH) are transferred from LDL to HDL. This process is regulated by the lipid 
composition and rigidity of the HDL surface. Specifically, HDL surface rigidity is determined 
by the ratios of SM:PC, FC:PL and saturated to polyunsaturated fatty acids (SFA:PUFA) [26]. 
Zerrad‐Saadi and colleagues have identified the HDL3 particle as a key mediator of LOOH 
transfer due its optimal surface rigidity and particle content [27].
ApoA‐I is likely the major HDL protein species involved in the removal of LOOH moieties 
from LDL. The methionine (Met) residues 112 and 148 of apoA‐I can reduce LOOHs to inac‐
tive lipid hydroxides (LOH) [28]. In addition, apoA‐I removes seeding LOOH molecules from 
LDL [29]. In addition to apoA‐I, other apolipoprotein and enzyme components of HDL, such 
as, apo E, apo J, apo A‐II, apo L‐1, apo F, apo A‐IV, PON1/3, PLTP and PAF‐AH, play a role in 
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its antioxidant function. Proteomic analyses from the Davidson laboratory [30] demonstrate 
that HDL3c contains all these proteins along with apo M, apo D, apo A‐II, SAA1,2 and 4 and 
apo C‐I and apo C‐II. This corroborates earlier studies showing that HDL3c has more potent 
antioxidant activity than other HDL subspecies [31, 32]. Thus, both lipid and protein compo‐
nents of HDL3c contribute to its antioxidant activity. Kontush et al. [32] have hypothesized 
that the protein components of HDL3c form a pocket which enables the transfer of LOOH 
from LDL which is further reduced by the concerted action of apolipoproteins and enzymes 
in this pocket [26].
Anti‐inflammatory properties of HDL: The role of inflammation in atherogenesis has been 
clearly established [33–35]. Acute and chronic inflammations are associated with monocyte 
adhesion/infiltration and endothelial cell activation [33–35]. HDL is known to suppress the 
lipopolysaccharide (LPS)‐induced secretion of interleukin‐6 (IL‐6), tumor necrosis factor‐α 
(TNF‐α), interferon‐γ (IFN‐γ) and other pro‐inflammatory mediators [36–38]. HDL also 
reduces inflammation by neutralizing endotoxin, further supporting its anti‐inflammatory 
role [39]. Thus, HDL exerts its anti‐inflammatory effect in multiple ways.
Regulation of endotoxicity: In the context of infection, Gram‐negative bacteria release LPS in the 
circulation which binds CD14 located in membrane rafts on cell surfaces. CD14 engagement 
facilitates the activation of toll‐like receptor 4 (TLR4) binding, resulting in the release of pro‐
inflammatory cytokines such as IL‐6 and TNF‐α. HDL is able to inhibit this initial activation 
step via binding to lipid A, a glycolipid component of LPS, thus preventing TLR4 activation. 
Gram‐positive bacteria release lipoteichoic acid (LTA) which, similar to LPS, binds CD14 and 
activates pro‐inflammatory signaling via the TLR2/6 pathway [40, 41]. HDL additionally con‐
tributes to the inactivation of LPS and LTA by disrupting membrane rafts. In this manner, 
HDL mediates cholesterol and phospholipid efflux which destabilizes rafts and prevents the 
assembly of receptor complexes for LPS and LTA [14, 40].
Regulation of macrophage function: Macrophages are a versatile group of cells that play a criti‐
cal role in regulating immunity, inflammation and lipid metabolism. Macrophage phenotype 
and function are regulated, in large part, by their environmental milieu [42–45]. On the basis 
of cell morphology and function, two populations of activated macrophages have been identi‐
fied [46]. The classically activated M1 macrophage is induced by LPS and Th1 cytokines such 
as IFN‐γ, interleukin‐2 (IL‐2) and TNF‐α [43, 44]. These cells are pro‐inflammatory and secrete 
inflammatory mediators (TNF‐α, IL‐1, IL‐6, IL‐15, IL‐18, IL‐23, IFN‐γ), stimulate inducible 
nitric oxide synthase (iNOS) and promote the formation of reactive oxygen and nitrogen spe‐
cies [47]. The second macrophage phenotype, the alternatively activated M2 macrophage, is 
induced by IL‐4, IL‐10, IL‐13 and glucocorticoid hormones [42–45]. M2 macrophages play 
an important role in the resolution of inflammation by inhibiting inflammatory cytokine 
expression and promoting wound healing [42–45]. HDL and apo A‐I have been shown to 
promote the formation of anti‐inflammatory M2 macrophages in human monocyte‐derived 
macrophages [48] and mice [49]. As mentioned in the previous section, HDL3 is a key media‐
tor of reverse cholesterol transport and possesses potent antioxidant properties. Reports 
from several laboratories suggest that HDL‐associated S1P inhibits inflammation via activa‐
tion of the PI3‐kinase/Akt signaling pathway [50–52]. Pretreatment of bone marrow‐derived 
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 macrophages (BMDMs) with S1P suppressed LPS‐induced secretion of TNF‐α, monocyte 
chemoattractant protein (MCP) and IL‐12 [53]. Additionally, Hughes and colleagues reported 
that S1P enhanced the activity of Arg1 and suppressed the NF‐kB‐mediated induction of 
iNOS [53]. These responses to S1P are associated with M2 macrophage polarization.
Regulation of mitochondrial function: The mitochondrion is a double‐membraned, energy‐pro‐
ducing organelle, which contains its own maternally inherited mitochondrial DNA [54–56]. 
Under normal conditions, the mitochondrial respiratory chain shuttles electrons through the 
respiratory complexes, consumes oxygen at Complex IV and pumps hydrogen ions from 
inside the mitochondria to the intermembrane space at Complexes I, III and IV. This allows 
ATP production to proceed at the level of Complex V (ATP synthase). Under normal condi‐
tions, oxidative phosphorylation is a tightly regulated process with heat and reactive oxygen 
species (ROS) being produced as byproducts.
In the presence of ox‐LDL and other oxidized lipids, the mitochondrion increases the for‐
mation of ROS, which can damage the mitochondria and other organelles causing cellular 
dysfunction and death. HDL, by virtue of its antioxidant properties, can decrease the cellu‐
lar damage caused by oxidized lipids. The HDL protein PON1 hydrolyzes cholesterol esters 
and phospholipids in oxidized lipoproteins [52, 57, 58] thus inhibiting mitochondrial damage 
in the presence of oxidized lipids [58]. Further, HDL‐associated apoA‐I has been implicated 
in electron transport chain maintenance and repair [59]. In apoA‐I null mice (apoA‐I‐/‐), an 
increase in coronary ischemia‐reperfusion injury is observed compared to wild‐type mice 
[59] and is associated with a decrease in the content of the mitochondrial protein Coenzyme 
Q (CoQ) in cardiomyocytes. CoQ normally supports oxidative phosphorylation by shuttling 
electrons from Complex II to Complex III. Exogenous administration of CoQ to apo‐A‐I‐/‐ mice 
attenuated myocardial infarct size compared to the injury response in untreated mice. These 
data indicate the importance of HDL, and specifically, apoA‐I in preserving mitochondrial 
structure and function.
Potential mechanisms by which HDL preserves mitochondrial function include activation of 
the Reperfusion Injury Salvage Kinase (RISK) pathway and the Survivor Activating Factor 
Enhancement (SAFE) cascade. These are cell survival pathways which are known to prevent 
mitochondrial damage in models of ischemic pre‐ and postconditioning [60]. Activation of 
STAT3 is an important component of the SAFE pathway and results in the downregulation 
of pro‐apoptotic factors Bax and Bad and upregulation of antiapoptotic factor Bcl‐2 and the 
antioxidants manganese superoxide dismutase and metallothionein [60, 61]. Further, STAT3 
is transported to the mitochondrion by the GRIM‐19 chaperone where it inhibits the release of 
cytochrome c and reduces cell death [62–64]. In a rodent model of coronary artery occlusion, 
the administration of apoA‐I was shown to decrease infarct size and inhibit mitochondrial 
morphological changes seen in the heart [60]. Further analyses showed that apoA‐I increased 
the phosphorylation of Akt and glycogen synthase kinase 3 beta (GSK3β), known mediators 
of the RISK and SAFE survival pathways.
The S1P component of HDL is also able to activate the RISK And SAFE pathways [51, 52, 
65]. Interestingly, studies conducted in neonatal rat cardiomyocytes showed that S1P is criti‐
cally required for the phosphorylation of STAT3. In contrast, STAT3 phosphorylation was 
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absent in cells treated with HDL that was deficient in S1P [65]. In addition, S1P stimulates 
the phosphorylation of the transcription factor, forkhead box O‐1 (FOXO‐1), which inhibits 
ROS formation and apoptosis in the phosphorylated form [66, 67]. These data suggest that 
HDL activates RISK and SAFE pathways and inhibits ROS, mitochondrial dysfunction and 
cell death.
Interestingly, S1P has also been shown to regulate mitochondrial Complex IV assembly and 
cellular respiration by interacting with mitochondrial prohibitin‐2 (PBH‐2) [68]. PBH‐2 acts 
as a scaffolding protein for mitochondria and its interaction with S1P during ischemic pre‐
conditioning of cardiomyocytes is essential for cardioprotection [68–70]. These data suggest 
that S1P can stabilize mitochondrial complexes and inhibit ROS formation, suggesting an 
alternate cardioprotective mechanism of S1P action.
Recent studies have suggested that other HDL‐associated apolipoproteins play a role in pre‐
serving mitochondrial structure and function. ApoJ is expressed ubiquitously and is present 
on small dense HDL3 particles [71–73]. It is considered to be an antioxidant due to the pres‐
ence of disulfide bonds that inhibit ROS‐induced injury and preserve mitochondrial function 
[74]. Further, apoJ has been implicated in activating Akt and GSK3β and the RISK survival 
pathway [71]. ApoM is found in association with approximately 5% of HDL particles where 
it confers several cytoprotective properties that include stimulating preβ‐HDL formation, 
facilitating reverse cholesterol transport and inhibiting LDL oxidation [75–78]. ApoM also 
plays an important role in the cytoprotective response to S1P by binding the sphingolipid and 
facilitating its incorporation into HDL particles [75, 79, 80]. It follows that overexpression of 
apoM in mice reduces infarct size in response to ischemia‐reperfusion injury and preserves 
mitochondrial function by increasing the HDL content of S1P.
4. Inflammation‐induced alterations in HDL structure
Changes in HDL sub‐species and their function have been reported in several disease states, 
including atherosclerosis [4], rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) 
[81, 82], diabetes [83], hypertension [84] and psoriasis [85–87]. Inflammation/infection triggers 
an APR that causes a reduction in HDL quantity and alterations in both its lipid and protein 
composition. Van Lenten and colleagues [88] first reported that HDL loses its ability to inhibit 
LDL oxidation during the APR, demonstrating that inflammation affects the structure and 
function of HDL.
Lipidome alterations: The phospholipid content of HDL is altered during the APR [89]. This 
may be due to an increase in the activity of secretory phospholipase 2 (sPLA
2
) [90, 91]. Acute 
phase HDL also contains lower amounts of PE and PI along with several species of LPC with 
different levels of saturation. An important feature of acute phase HDL is that it contains 
oxidized phospholipids generated by the actions of transition metal ions, free radicals and 
hypochlorous acid (HOCl) [92, 93]. Formation of acute phase HDL in patients with coronary 
heart disease is also associated with a reduction in SM content [94]. An increase in triglycer‐
ides with a decrease in cholesteryl esters is also commonly observed in acute phase HDL [89].
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Proteome alterations: Several changes in HDL‐associated proteins arise in response to inflam‐
mation (Table 2). While a reduction in apo A‐I represents perhaps the most prominent change 
in HDL composition, data suggest that the lipoprotein content of SAA may increase up to 1000‐
fold [85]. Endotoxin and inflammatory cytokines (TNF‐α, IL‐1β and IL‐6) decrease the expres‐
sion of apoA‐I which leads to a decrease in circulating HDL concentration [95, 96]. In addition, 
an increase in the synthesis of SAA results in the displacement of apoA‐I from acute phase HDL 
[85]. Inflammation further decreases HDL levels by inducing the upregulation of sPLA
2
 which 
degrades phospholipid components of the lipoprotein particle [89]. Loss of LCAT activity [97, 
98] reduces the cholesterol carrying capacity of HDL by preventing the formation of cholesterol 
esters. Finally, PON1 activity is reduced by inflammation in patients with RA, SLE and psoriasis 
and infections and is associated with a reduction in the antioxidant capacity of HDL [99–102].
The presence of apoM in HDL particles is thought to contribute to atheroprotection [103]. LPS 
and inflammatory cytokines, however, attenuate apoM mRNA levels and protein expression 
in Hep3B cells [104]. A decrease in serum apoM is also observed in patients with sepsis and 
HIV infections [104]. Further, a reduction in apoM reduces the association of S1P with HDL 
resulting in degradation of anti‐inflammatory function [103].
The association of other apolipoproteins with HDL may impair the function of the lipopro‐
tein. ApoO is incorporated by HDL, LDL and VLDL particles [105]. Data suggest that apoO 
provides structural stability for mitochondria by stabilizing the inner mitochondrial mem‐
brane and cristae [105]. Other data, however, show that overexpression of apoO degrades 
mitochondrial protein and increases cardiac dysfunction in hypercholesterolemic mice [106]. 
In cardiomyocyte cultures, upregulation of apoO was associated with an increase in ROS and 
apoptosis compared to control cells that were apoO‐deficient [106]. ApoC is an additional, 
exchangeable apolipoprotein associated with HDL and apoB‐containing lipoproteins. In iso‐
Proteinsa Lipidsb
Increased Decreased Increased Decreased
Serum Amyloid A (SAA) Apo A‐I Triglycerides Total lipid
Apo J Apo A‐II FC Phospholipids
sPLA
2
Apo C LPC CE
Apo E Apo M FFA SM
Ceruloplasmin LCAT
PAF‐AH CETP
LBP Transferrin
Apo A‐IV Hepatic lipase
Apo A‐V Paraoxanase I
a Adapted from Refs. [87, 96, 97, 104].
b Adapted from Refs. [15, 89, 94].
Table 2. Inflammation‐induced changes in HDL composition.
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lated rat liver mitochondria, addition of the apoC‐III isoform was shown to inhibit mitochon‐
drial oxygen consumption and attenuate ATP formation [107]. Another study showed that 
enrichment of HDL with apoC‐I stimulates cytochrome c release, caspase 3 cleavage and cell 
death in human aortic smooth muscle cells [108]. Finally, apoC‐I enrichment of HDL is associ‐
ated with a reduction in HDL‐associated apoA‐I, suggesting that loss of apoA‐I and its cyto‐
protective effects is a component of apoC‐I‐mediated cell injury [107, 108]. Clearly, additional 
in vitro and in vivo studies are required to define the mechanistic role of specific apolipopro‐
tein species in the development of inflammatory injury.
5. Functional consequences of acute phase HDL formation
Changes in HDL lipid and protein composition induced by the APR impair normal HDL 
function resulting in the formation of “dysfunctional” HDL.
Loss of cholesterol efflux ability: Since cholesterol efflux involves the participation of apoA‐I, 
phospholipids, LCAT and CETP, several aspects of dysfunctional HDL inhibit normal reverse 
cholesterol transport. The reduction in apoA‐I and increase in HDL‐associated SAA impair 
cholesterol efflux capacity [109, 110]. The presence of SAA on HDL increases foam cell forma‐
tion by facilitating the uptake of cholesterol esters by macrophages. At the level of the hepa‐
tocyte, this acute phase HDL impairs cholesterol uptake and degradation [111]. Decreased 
content of LCAT, PL and CETP on HDL also contribute to a loss of efflux activity as does the 
oxidative modification of apoA‐I [112, 113].
Impairment of antioxidative activity: An increase in TG and decrease in cholesterol ester 
content in dysfunctional HDL leads to a change in conformation of the HDL particle. The 
formation of a TG‐rich HDL particle induces structural changes in apoA‐I and decreases its 
stability [114]. Additionally, an increase in SAA and loss of PON1 result in a reduced antioxi‐
dant capacity of the HDL particle.
Attenuation of anti‐inflammatory activity: Dysfunctional HDL has an impaired capacity to 
counteract the action of LPS and inflammatory cytokines. The ability to regulate membrane 
raft cholesterol content is reduced and can thus enhance TLR activation in response to pro‐
inflammatory mediators [115]. Oxidation of apoA‐I also results in a loss of functionality with 
respect to its ability to efflux cholesterol. The protein and lipid alterations observed (reduced 
apoA‐I, cholesterol ester, PON1 and LCAT levels and increased TG and SAA levels) are also 
responsible for the attenuated anti‐inflammatory activity observed with dysfunctional HDL.
6. Conclusions
HDL plays an important role in regulating atherogenesis via its ability to mediate reverse 
cholesterol transport. The ability of HDL to reduce inflammatory injury and oxidant stress 
has also been shown to reduce CVD risk. As discussed in this review, both protein and 
lipid components of the lipoprotein particle play critical roles in attenuating inflammation. 
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Identification of these cytoprotective HDL components has been facilitated by recent pro‐
teomic analyses. Under pathological conditions, HDL levels may be reduced and the lipo‐
protein may undergo biochemical and structural modification resulting in the formation of 
dysfunctional HDL with pro‐inflammatory properties. It has been suggested that the anti‐
inflammatory status of HDL may be of greater predictive value for CVD risk than HDL levels 
per se [116, 117]. Therapeutic approaches that increase the functional properties of HDL may 
thus be superior to simply raising circulating HDL. Unfortunately, specific and reliable bio‐
markers for anti‐inflammatory HDL have not been identified. Under ex vivo conditions, the 
quality of HDL can be assessed by studying lipoprotein effects of processes such as mono‐
cyte chemotaxis and endothelial inflammation. These assays, however, are cumbersome and 
time‐consuming. Despite these drawbacks, there is significant interest in developing new 
pharmacotherapies that positively impact circulating lipoproteins. Randomized clinical tri‐
als have assessed effects of several classes of drugs on plasma cholesterol levels in patients at 
risk. Niacin and statins significantly lower LDL and were shown to induce modest increases 
in HDL [8]. Residual risk, however, may be present in patients with persistently low HDL 
despite a reduction in LDL. CETP inhibitors have been shown to increase HDL levels in ani‐
mal models and in human subjects with low HDL [118, 119]. The ILLUMINATE trial tested 
effects of the CETP inhibitor torcetrapib on HDL and outcomes in high risk patients but was 
terminated early due to an increase in mortality due to off‐target effects [7]. In ongoing stud‐
ies, the antiatherogenic and anti‐inflammatory effects of reconstituted HDL therapy as well as 
apolipoprotein mimetics are being evaluated. Recent exciting data also show that HDL serves 
as a carrier for functional miRNAs that suppress inflammation at the level of the endothelial 
cell [120]. miRNAs have also been identified that regulate HDL biogenesis [121]. These recent 
observations may lay the foundation for a new field of miRNA‐based HDL therapeutics.
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